FeRx, Inc. - Product Pipeline Review - Q4 2010

Global Markets Direct, November 2010, Pages: 39

FeRx, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “FeRx, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- FeRx, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of FeRx, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of FeRx, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the FeRx, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate FeRx, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of FeRx, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the FeRx, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with FeRx, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of FeRx, Inc. and identify potential opportunities in those areas.

List of Tables
List of Figures
FeRx, Inc. Snapshot
FeRx, Inc. Overview
Key Information
Key Facts
FeRx, Inc. – Research and Development Overview
Key Therapeutic Areas
FeRx, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
FeRx, Inc. – Pipeline Products Glance
FeRx, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
FeRx, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
FeRx, Inc. – Drug Profiles
MTC-DOX_
Product Description
Mechanism of Action
R&D Progress
MTC-Melphalan
Product Description
Mechanism of Action
R&D Progress
MTC-Mitomycin C
Product Description
Mechanism of Action
R&D Progress
MTC-Oxaliplatin
Product Description
Mechanism of Action
R&D Progress
MTC-Yttrium
Product Description
Mechanism of Action
R&D Progress
MTC-Amphotericin B
Product Description
Mechanism of Action
R&D Progress
MTC-Camptothecins
Product Description
Mechanism of Action
R&D Progress
MTC-Gemcitabine
Product Description
Mechanism of Action
R&D Progress
MTC-Genetic Vectors
Product Description
Mechanism of Action
R&D Progress
MTC-Octreotide
Product Description
Mechanism of Action
R&D Progress
MTC-Taxanes
Product Description
Mechanism of Action
R&D Progress
FeRx, Inc. – Pipeline Analysis
FeRx, Inc. – Pipeline Products by Therapeutic Class
FeRx, Inc. Pipeline Products By Target
FeRx, Inc. – Pipeline Products by Molecule Type
FeRx, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Jan 14, 2004: FeRx Files For Phase I/II Clinical Testing Of Magnetarg System To Treat Lung Cancer
Oct 28, 2003: FeRx Receives Phase I SBIR Grant To Develop MagneTarg System To Treat Pancreatic Tumors
Oct 04, 2000: FeRx Receives SBIR Grant For Study Of Magnetic Targeting Of Radioactive Microparticles
Oct 04, 2000: FeRx Receives SBIR Grant For Study Of Magnetic Targeting Of Radioactive Microparticles
Oct 04, 2000: FeRx Receives SBIR Grant For Study Of Magnetic Targeting Of Radioactive Microparticles
Oct 04, 2000: FeRx Receives SBIR Grant For Study Of Magnetic Targeting Of Radioactive Microparticles
Financial Deals Landscape
FeRx, Inc. Detailed Deal Summary
Venture Financing
FeRx Secures $15 Million In Series D Financing
FeRx Secures $6.1 Million In Series C Financing
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• Education Services - Global Strategic Business Report
• Generic Defense Strategies: Lifecycle Management Strategies to Maximize Revenue in the Face of Growing Generic Competition
• eLEARNING - Global Strategic Business Report
• Aerospace and Defense Industry - Global Strategic Business Report
• Private Tutoring - Global Strategic Business Report
• Charter Schools - Global Outlook
• Commercial And Military Flight Simulation - Global Strategic Business Report
• Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans
• Sports and Fitness Nutrition - Global Strategic Business Report
• Aerospace and Defence Industry - Global Strategic Business Report